AstraZeneca withdraws its EU application for Truqap in PTEN-deficient prostate cancer after a CHMP provisional opinion. Read ...
A2 Biotherapeutics' MSLN-targeting A2B694 CAR T therapy produced a 12-month-plus complete response in one NSCLC patient. Read ...
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up ...
AN2 Therapeutics receives FDA IND clearance for epetraborole in polycythemia vera, completing approvals in Australia, India ...
Pfizer Q3 2026 earnings: second positive Elrexfio Phase III readout, atirmociclib tolerability data and mevrometostat delay.
Servier's sevasemten missed its Phase III GRAND CANYON primary endpoint in Becker muscular dystrophy. Read how these results ...
Camurus has dosed the first patient in LUNAR-2, a Phase IIb study of monthly semaglutide depot CAM2056 for obesity. Explore ...
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) will discontinue its Phase II TOPAS-MSA study of emrusolmin (TEV-'286), an orally administered small ...
Columbia researchers show deleting certain sugar transport genes helps E. coli colonize tumors better. Learn how this could ...
Ensem registers a Phase I/II trial of oral pan-KRAS inhibitor ETX-929 for KRAS-altered solid tumors. Learn how it's tested ...
Beijing Mabworks' MBS314 trispecific antibody (GPRC5D, BCMA, CD3) cleared by China's NMPA for first-in-human myeloma trial.
Specific Biologics closes a $35M Series A to advance its Dualase gene-editing therapy into a Phase I/II trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results